BullBD Old Apps Site
Home
Details Chart Today news Share news Top gainer Top Looser Upcoming events
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0 1 2 3 4 5 6 7 8 9 All
Bank Cement Ceramics Sector Corporate Bond Engineering Financial Institutions Food & Allied Fuel & Power IT Sector Insurance Jute Life Insurance Miscellaneous Mutual Funds Paper & Printing Pharmaceuticals & Chemicals Services & Real Estate Tannery Industries Telecommunication Textile Travel & Leisure All
  • Details
  • Chart
  • News

SQURPHARMA

All Eps Dividend Board Agm Q1 Q2 Q3

SQURPHARMA 24-Jan-2021

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 28, 2021 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended on December 31, 2020.

SQURPHARMA 29-Jan-2020

(Q2 Un-audited): Consolidated EPS was Tk. 4.18 for October-December 2019 as against Tk. 3.70 for October-December 2018; Consolidated EPS was Tk. 8.16 for July-December 2019 as against Tk. 7.46 for July-December 2018. Consolidated NOCFPS was Tk. 5.88 for July-December 2019 as against Tk. 6.83 for July-December 2018. Consolidated NAV per share was Tk. 84.12 as on December 31, 2019 and Tk. 80.40 as on June 30, 2019.

SQURPHARMA 23-Jan-2020

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 29, 2020 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended on December 31, 2019.

SQURPHARMA 30-Jan-2019

(Q2 Un-audited): Consolidated EPS was Tk. 3.96 for October-December, 2018 as against Tk. 3.62 for October-December, 2017; Consolidated EPS was Tk. 7.98 for July-December, 2018 as against Tk. 7.43 for July-December, 2017. Consolidated NOCFPS was Tk. 7.32 for July-December, 2018 as against Tk. 8.09 for July-December, 2017. Consolidated NAV per share was Tk. 77.90 as on December 31, 2018 and Tk. 73.28 as on June 30, 2018.

SQURPHARMA 24-Jan-2019

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 30, 2019 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended on December 31, 2018.

SQURPHARMA 30-Jan-2018

(Q2 Un-audited): Consolidated EPS was Tk. 3.87 for October-December, 2017 as against Tk. 3.33 for October-December, 2016; Consolidated EPS was Tk. 7.95 for July-December, 2017 as against Tk. 6.62 for July-December, 2016. Consolidated NOCFPS was Tk. 8.66 for July-December, 2017 as against Tk. 7.94 for July-December, 2016. Consolidated NAV per share was Tk. 71.31 as on December 31, 2017 and Tk. 66.49 as on June 30, 2017.

SQURPHARMA 24-Jan-2018

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 30, 2018 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended on December 31, 2017.

SQURPHARMA 29-Jan-2017

(Q2 Un-audited): Consolidated EPS was Tk. 3.58 for October-December, 2016 as against Tk. 3.21 for October-December, 2015; Consolidated EPS was Tk. 7.11 for July-December, 2016 as against Tk. 6.10 for July-December, 2015. Consolidated NOCFPS was Tk. 8.54 for July-December, 2016 as against Tk. 8.93 for July-December, 2015. Consolidated NAV per share was Tk. 63.00 as of December 31, 2016 and Tk. 59.13 as of June 30, 2016.

SQURPHARMA 23-Jan-2017

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 29, 2017 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended on December 31, 2016.

SQURPHARMA 28-Oct-2015

(Q2 Un-audited): Consolidated EPS was Tk. 3.18 for July-September, 2015 as against Tk. 2.09 for July-September, 2014; Consolidated EPS was Tk. 6.09 for April-September, 2015 as against Tk. 4.32 for April-September, 2014. Consolidated NOCFPS was Tk. 6.87 for April-September, 2015 as against Tk. 3.94 for April-September, 2014. Consolidated NAV per share was Tk. 53.37 as of September 30, 2015 and Tk. 49.86 as of March 31, 2015.

Previous Next page